10.1016/j.semcdb.2012.03.017 117 ZhangG.YaoQ.LongC.YiP.SongJ.WuL.et al (2025)
Glucagon-like peptide-1 (GLP-1) receptor agonist therapy helps prevent kidney events and reduce mortality in patients with type 2 diabetes and chronic kidney disease (CKD) irrespective of whether or not they have established atherosclerotic cardiovascular disease (ASCVD) or high total CVD risk, a secondary analysis of the FLOW trial suggests
Now, the third most commonly used peptide in this category of what I'm calling type one growth hormone secreting peptides is CJC1295
Sequential use completing a Tirzepatide research cycle and then transitioning to a Retatrutide protocol is a more logical framework and is being studied in ongoing trials
Singapore: Springer (2024)
Supports Cellular Energy & Longevity Stacks combining Sermorelin and NAD+ support mitochondrial function, cellular repair, and growth hormone signaling, targeting the root causes of fatigue, poor sleep, and age-related metabolic decline